证券代码：600572 证券简称：康恩贝 公告编号：临 2025-036 浙江康恩贝制药股份有限公司 关于注销回购股份实施结果暨股份变动公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者重大遗漏，并对 其内容的真实性、准确性和完整性承担法律责任。 一、回购审批情况和回购方案内容 2024 年 1 月 22 日，浙江康恩贝制药股份有限公司(以下简称"公司")召开第十 届董事会第三十七次（临时）会议，审议通过《关于以集中竞价交易方式回购公司 股份的议案》，并于 2024 年 1 月 23 日在《中国证券报》《上海证券报》《证券时报》 和上海证券交易所网站 www.sse.com.cn（指定信息披露媒体和披露网址下同）披露 了临 2024—006 号《公司关于以集中竞价交易方式回购股份方案的公告》。2024 年 1 月 27 日，公司披露了临 2024—008 号《公司关于以集中竞价交易方式回购股份的回 购报告书》。本次股份回购方案的主要内容如下：同意公司使用自有资金通过上海证 券交易所以集中竞价交易方式回购公司股份，用于实施股权激励。拟回购股份的资 金总额不低于 20,000 万元（含） ...

Core Points - The company announced the results of the stock option incentive plan for the second quarter of 2025, with a total of 492,437 shares exercised [1][8] - The stock option plan was initially approved in September 2022, allowing for the grant of 70 million stock options [1][2] - The exercise price of the stock options was adjusted multiple times, with the latest adjustment setting it at 3.78 yuan per share for the initial grant and 5.07 yuan for reserved options [3][4][5] Summary by Sections Incentive Plan Overview - The stock option incentive plan was approved by the board and supervisory committee in September 2022, with detailed disclosures made on the Shanghai Stock Exchange [1][2] - The plan allows for the grant of stock options to 537 individuals, with a total of 62.475 million options registered [1][2] Adjustments to Exercise Price - The exercise price was adjusted from 4.13 yuan to 3.98 yuan in June 2023 following a cash dividend distribution [2][3] - Further adjustments were made in July 2024, reducing the exercise price to 3.78 yuan for initial options and 5.07 yuan for reserved options [4][5] Exercise Results - As of the second quarter of 2025, a total of 1,486,712.7 shares were exercised, with the total number of shares exercised reaching 49,243.7 shares [6][7] - The shares obtained through the exercise will be tradable two trading days after the exercise date [7] Impact on Share Capital Structure - The total number of shares increased from 2,584,412,009 to 2,584,904,446 after the exercise, with the distribution of shares remaining compliant with listing requirements [7][8] - The company raised 1.844387 million yuan from the exercise of stock options [7]

2025年第二季度，公司本次激励计划激励对象行权且完成股份过户登记的股票 数量合计为49.2437万股。有关情况公告如下： 一、本次激励计划已履行的决策程序及相关信息披露 （一）2022年9月15日，公司十届董事会第二十二次（临时）会议和十届监事会 第十三次（临时）会议分别审议通过了《关于<浙江康恩贝制药股份有限公司2022年 股票期权激励计划（草案）>及摘要的议案》及其他相关议案，公司独立董事、监事 会 、 律师 均 发 表 了相 关 意 见 ，并 于 2022 年9 月 16 日 在 上海 证 券交 易 所 网 站 www.sse.com.cn和《中国证券报》《上海证券报》《证券时报》（以下统称：公司 指定信息披露媒体）进行了详尽披露。（公告编号：临2022-046、临2022-047、临 2022-048） 证券代码：600572 证券简称：康恩贝 公告编号：临2025-035 浙江康恩贝制药股份有限公司 关于2025年第二季度股票期权激励计划 2、本次行权股票上市流通时间：采用自主行权方式行权，激励对象（除公司董事、高级管 理人员外）行权所得股票于行权日（T 日）后的第二个交易日（T+2）日可上市交易 ...

Core Insights - The demand for grape seed health products is increasing due to rising living standards and health awareness among consumers [1][16] - The market size of grape seed health products in China is projected to grow from 5 billion yuan in 2019 to 9 billion yuan by 2024, with a compound annual growth rate of 12% [1][16] - Technological advancements in extraction efficiency and purity are supporting the growth of the grape seed health product market [1][16] Industry Overview - Grape seed health products are derived from grape seeds and contain beneficial components such as vitamins, minerals, amino acids, and antioxidants, offering various health benefits [3][10] - The industry can be categorized by product form (tablets, capsules, liquid), efficacy (antioxidant, anti-aging), and usage scenarios (daily health, beauty, sports nutrition) [5][10] Market Dynamics - The grape seed health product market is experiencing rapid expansion due to the growth of e-commerce and diversified marketing channels [1][16] - The increase in grape production in China, from 13.16 million tons in 2015 to 16.17 million tons in 2023, is expected to provide ample raw materials for grape seed health products [12][14] Regulatory Environment - Recent policies in China aim to promote the integration of the food industry with health and wellness sectors, enhancing the market for functional foods and health products [6][9] Competitive Landscape - Major players in the grape seed health product market include well-known domestic brands such as汤臣倍健 (Tongrentang), 康恩贝 (Kang En Bei), and 九芝堂 (Jiu Zhi Tang), as well as international brands like Nature's Way and NOW Foods [18][19] - Companies are enhancing their competitiveness through improved production technologies and brand marketing strategies [18][19] Consumer Trends - There is a notable increase in consumer demand for high-quality grape seed health products, particularly among women and young adults aged 18 to 35, who represent 83.7% of the health supplement market [24][25] - Consumers are increasingly focused on product quality, efficacy, and safety, necessitating continuous improvement in product formulations [24][25] Future Outlook - The industry is expected to benefit from technological advancements that enhance product absorption and bioavailability [25][26] - The trend of online and offline integration in sales channels is becoming crucial for market growth, providing consumers with a more convenient shopping experience [26][27] - International expansion is a growing trend, with Chinese companies leveraging their resources and technology to compete in global markets [27]

Core Insights - EVA Pharmaceuticals and Zhejiang Jinhua Conba Biopharmaceutical Group have signed a strategic supply agreement to enhance cross-border cooperation in the healthcare sector, aiming to build a more resilient and accessible medical supply chain [1][3] Group 1: Strategic Partnership - The agreement was signed during the 2025 CPHI China event, representing high-level collaboration between two influential companies in their respective regions [3] - The partnership aims to support a more sustainable, flexible, and secure pharmaceutical supply chain, ultimately increasing accessibility for patients in emerging markets [3] - Both companies are committed to long-term supply reliability, technological excellence, and patient-centered delivery models [3] Group 2: Company Profiles - EVA Pharmaceuticals focuses on improving global access to affordable, high-quality medicines, emphasizing innovation, development, and sustainable accessibility [4] - The company operates four internationally recognized manufacturing facilities, producing over one million medical products daily, with a workforce of over 5,000 professionals [4] - EVA Pharmaceuticals' product portfolio targets twelve therapeutic areas, including infectious diseases, metabolic health, oncology, and pediatrics, addressing both local and international health needs [4] Group 3: Market Impact - The collaboration is expected to set a new benchmark for trust-based cross-border supply cooperation amid growing global demand for supply chain resilience [3] - The partnership combines EVA Pharmaceuticals' regional coverage with Conba's manufacturing capabilities to create a sustainable impact in key markets [3]

Core Viewpoint - The legal opinion issued by Beijing Guantao (Hangzhou) Law Firm confirms that Zhejiang Kang En Bei Pharmaceutical Co., Ltd.'s differentiated dividend distribution plan for the year 2024 complies with relevant laws and regulations, ensuring no harm to the interests of the company and its shareholders [8]. Group 1: Differentiated Dividend Distribution - The differentiated dividend distribution is based on the company's net profit of RMB 405,473,540.71 for 2024, with a 10% legal surplus reserve of RMB 40,547,354.07 being deducted [6][7]. - The company plans to distribute a cash dividend of RMB 1.50 (including tax) for every 10 shares to all shareholders, calculated based on the total share capital after excluding the shares held in the repurchase account [6][7]. Group 2: Share Repurchase Details - The company announced a share repurchase plan with a total fund of no less than RMB 200 million and no more than RMB 400 million, with the repurchase period set for six months from the board's approval date [4][5]. - As of July 21, 2024, the company completed the repurchase of 63,579,048 shares, accounting for 2.47% of the total share capital, with an average repurchase price of RMB 4.72 per share [5][6]. Group 3: Legal Compliance and Conclusion - The law firm confirms that the differentiated dividend distribution adheres to the Company Law, Securities Law, and other relevant regulations, ensuring that it does not harm the interests of the company and its shareholders [8]. - The legal opinion is intended solely for the purpose of the differentiated dividend distribution and must not be used for any other purpose without prior written consent from the law firm [3].

Core Viewpoint - The company has approved a differentiated profit distribution plan for the fiscal year 2024, which includes a cash dividend of 1.50 yuan per 10 shares for eligible shareholders [2][4]. Distribution Plan - The distribution will be based on a total share capital of 2,584,790,946 shares, excluding 63,579,048 shares held in the company's repurchase account, resulting in a base of 2,521,211,898 shares for the cash dividend calculation [2][3]. - The total cash dividend to be distributed amounts to 378,181,784.7 yuan (including tax) [2]. Dividend Calculation - The cash dividend per share is calculated to be approximately 0.1463 yuan after adjusting for the total share capital [3][5]. - The reference price for ex-dividend trading will be adjusted based on the formula provided, taking into account the cash dividend and the change in circulating shares [5]. Implementation Method - Cash dividends will be distributed through the China Securities Depository and Clearing Corporation Limited Shanghai Branch to registered shareholders as of the record date [5][6]. - Shareholders who have not completed designated transactions will have their dividends held by the clearing company until the transactions are completed [5]. Taxation Information - Individual shareholders holding shares for over one year will be exempt from personal income tax on dividends, while those holding for less than one month will have their dividends fully taxed [7][8]. - Qualified Foreign Institutional Investors (QFIIs) will have a 10% withholding tax applied, resulting in a net cash dividend of 0.135 yuan per share [8][9]. Future Adjustments - Following the completion of the 2024 profit distribution, the company will adjust the exercise price of its stock option incentive plan in accordance with regulatory requirements [10].

北京观韬（杭州）律师事务所 关于浙江康恩贝制药股份有限公司 差异化分红事项的法律意见书 致：浙江康恩贝制药股份有限公司 北京观韬（杭州）律师事务所（以下简称"本所"）接受浙江康恩贝制药股份有 限公司（以下简称"公司"或"康恩贝"）委托，依据《中华人民共和国公司法》（以 下简称"《公司法》"）、《中华人民共和国证券法》（以下简称"《证券法》"）、 中国证券监督管理委员会（以下简称"中国证监会"）发布的《上市公司股份回购规 则》（以下简称"《回购规则》"）、《律师事务所从事证券法律业务管理办法》《律 师事务所证券法律业务执业规则（试行）》等法律、行政法规、规范性文件及现行有 效的《公司章程》等规定，就公司 2024 年年度利润分配实施所涉及的差异化分红（以 下简称"本次差异化分红"）相关事宜出具法律意见书。 本所是依法注册具有执业资格的律师事务所，有资格就中国法律、法规、规范性 文件的理解和适用出具法律意见。 本所及经办律师依据《证券法》《律师事务所从事证券法律业务管理办法》和《律 师事务所证券法律业务执业规则（试行）》等规定及本法律意见书出具日以前已经发 生或者存在的事实，严格履行了法定职责，遵循了勤勉尽责和诚 ...

证券代码：600572 证券简称：康恩贝 公告编号：2025-034 浙江康恩贝制药股份有限公司 2024年年度权益分派实施公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者重大遗 漏，并对其内容的真实性、准确性和完整性承担法律责任。 A 股每股现金红利0.15元 相关日期 | 股份类别 | 股权登记日 | 最后交易日 | 除权（息）日 | 现金红利发放日 | | --- | --- | --- | --- | --- | | Ａ股 | 2025/6/24 | － | 2025/6/25 | 2025/6/25 | 差异化分红送转： 是 一、通过分配方案的股东大会届次和日期 本次利润分配方案经浙江康恩贝制药股份有限公司（以下简称"公司""本公 司"）2025 年 5 月 23 日的2024年年度股东大会审议通过。 二、分配方案 （一）发放年度：2024年年度 重要内容提示： 每股分配比例 （二）分派对象： 截至股权登记日下午上海证券交易所收市后，在中国证券登记结算有限责任 公司上海分公司（以下简称"中国结算上海分公司"）登记在册的本公司全体股东。 根据中国证监会《上市公司股份回购规则 ...

Core Viewpoint - The legal opinion letter issued by Shanghai Dongfang Huayin Law Firm confirms that Zhejiang Kang En Bei Pharmaceutical Co., Ltd. has complied with relevant laws and regulations regarding the adjustment of the exercise price for its 2022 stock option incentive plan [1][8]. Group 1: Company Qualifications - The company is a legally established joint-stock company listed on the Shanghai Stock Exchange, with a total share capital of 137.2 million shares, including 40 million A-shares [3]. - The company does not fall under any prohibitive conditions for implementing stock incentives as outlined in the Management Measures [4]. Group 2: Approval and Authorization - The company has completed the necessary approval and authorization procedures for adjusting the exercise price of the stock options under the 2022 incentive plan, in accordance with the Management Measures and the incentive plan [5][8]. Group 3: Adjustment Details - The exercise price for the stock options has been adjusted from 3.78 yuan to 3.63 yuan per share for the first grant, and from 5.07 yuan to 4.92 yuan per share for the reserved grant, following the company's profit distribution plan [6][8].